🇺🇸 FDA

Company profile · Sponsor

Rhythm

Rhythm Pharmaceuticals Netherlands B.V.

RYTM · NYSE pharma BOSTON, MA, EU
Pipeline
24
Drugs
2
Patents
8

Quick answer

Rhythm (RYTM) is a pharma company. headquartered in BOSTON, MA, EU. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 2 drugs, and 8 patents to this profile..

Company facts

Ticker RYTM
Exchange NYSE
Company type pharma
Headquarters BOSTON, MA, EU
SEC CIK 0001649904

Pipeline (24)

Search pipeline →

  1. CRT with triple site ventricular stimulation

    Rhythm

    Heart Failure

    phase 3 other completed

    1 trial

  2. Class I or III Antiarrhythmic Medications

    Rhythm

    Atrial Fibrillation

    phase 3 small molecule completed

    1 trial

  3. Coronary artery bypass grafting

    Rhythm

    Ischemic Heart Failure

    phase 3 other completed

    1 trial

  4. Flecainide or Sotalol or Propafenone

    Rhythm

    Paroxysmal Atrial Fibrillation

    phase 3 small molecule completed

    1 trial

  5. Medtronic Talent Stent-Graft-System

    Rhythm

    Aortic Diseases

    phase 3 other completed

    1 trial

  6. Setmelanotide

    Rhythm

    Obesity

    phase 3 small molecule active

    1 trial

  7. Setmelanotide

    Rhythm

    Bardet-Biedl Syndrome

    phase 3 small molecule completed

    1 trial

  8. Setmelanotide

    Rhythm

    Obesity Associated With Defects in Leptin-melanocortin Pathway

    phase 3 small molecule active

    2 trials

  9. Setmelanotide

    Rhythm

    Bardet Biedl Syndrome (BBS)

    phase 3 small molecule completed

    1 trial

  10. Setmelanotide

    Rhythm

    Hypothalamic Obesity

    phase 3 small molecule active

    3 trials

  11. Setmelanotide

    Rhythm

    Pro-opiomelanocortin (POMC) Deficiency Obesity

    phase 3 small molecule completed

    1 trial

  12. Setmelanotide

    Rhythm

    Leptin Receptor Deficiency Obesity

    phase 3 small molecule completed

    1 trial

  13. Setmelanotide 2 mg

    Rhythm

    Bardet-Biedl Syndrome

    phase 3 small molecule completed

    1 trial

  14. Ventricular Assist Device System

    Rhythm

    Heart Failure

    phase 3 other completed

    1 trial

  15. Bivamelagon

    Rhythm

    Hypothalamic Obesity

    phase 2 small molecule active

    1 trial

  16. Diuretics

    Rhythm

    Heart Failure

    phase 2 small molecule completed

    1 trial

  17. LB54640

    Rhythm

    Hypothalamic Obesity

    phase 2 small molecule completed

    1 trial

  18. Medtronic PrimeADVANCED Neurostimulator

    Rhythm

    Heart Failure

    phase 2 other completed

    1 trial

  19. PCI

    Rhythm

    Myocardial Infarction

    phase 2 other completed

    1 trial

  20. Part A: RM-718 or placebo (matched to specific RM-718 dose cohort)

    Rhythm

    Hypothalamic Obesity

    phase 2 small molecule active

    1 trial

  21. Setmelanotide

    Rhythm

    Genetic Obesity

    phase 2 small molecule completed

    2 trials

  22. Setmelanotide

    Rhythm

    Overweight and Obesity

    phase 2 small molecule completed

    1 trial

  23. Setmelanotide

    Rhythm

    Hypertriglyceridemia

    phase 2 small molecule completed

    1 trial

  24. Setmelanotide

    Rhythm

    Overweight

    phase 2 small molecule completed

    1 trial

Drugs (2)

Search drugs →

  1. setmelanotide

    IMCIVREE

    A08AA

  2. setmelanotide acetate

    IMCIVREE

    SUBCUTANEOUS approved

Patents (8)

Search patents →

  1. US 12285460

    Pharmaceutical compositions

    Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12263202

    Method of treating melanocortin-4 receptor pathway-associated disorders

    Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12077612

    Peptide compositions

    Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11702448

    Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers

    Expires Mon Jul 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11129869

    Pharmaceutical compositions

    Expires Mon Sep 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10960046

    Method of treating melanocortin-4 receptor pathway-associated disorders

    Expires Mon Mar 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10954268

    Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers

    Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10858399

    Peptide compositions

    Expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Rhythm?

Rhythm (RYTM) is a pharma company. headquartered in BOSTON, MA, EU. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 2 drugs, and 8 patents to this profile..

What pipeline programs does Rhythm sponsor?

We track 24 ClinicalTrials.gov-linked programs for Rhythm, including CRT with triple site ventricular stimulation and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Rhythm company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.